Allarity Therapeutics

New Diagnostic Platform Accurately Predicts Cancer Drug Response

About this Event

Allarity Therapeutics (NASDAQ: ALLR) is a clinical-stage precision medicine company committed to enhancing patient outcomes through improved decision-making and personalized cancer care.

Allarity has developed a proprietary Drug Response Predictor (DRP®) technology. It is a first-in-class, highly validated diagnostic platform that models human tumor biology and can help predict whether a cancer patient will respond to a particular drug or not. The company is deploying a DRP companion diagnostic to select patients for its lead program, Stenoparib. This allows the trial to focus on and treat patients most likely to benefit from treatment. It also quickens clinical development and enhances the probability that a drug will receive FDA approval.

Stenoparib is an orally available, small molecule inhibitor that uniquely targets enzymes in tumor cells. Early Phase 2 data indicate durable clinical benefit in women with advanced ovarian cancer. The American Cancer Society estimates that more than 19,000 women received a new diagnosis of ovarian cancer and nearly 13,000 women have died this year due to the disease in 2024.

Register today to join this event with Allarity Founder, CEO and Director, Thomas Jensen, to hear how how their Drug Response Predictor platform will be a game changer in cancer diagnostics and treatment.

Hosted by Force Family Office CEO, Steven Saltzstein

Video On Demand

– Recorded

January 7

SHARE THIS EVENT

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.